1887

Chapter 16 : Acquired Immunity against Fungi

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in
Zoomout

Acquired Immunity against Fungi, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555817978/9781555812140_Chap16-1.gif /docserver/preview/fulltext/10.1128/9781555817978/9781555812140_Chap16-2.gif

Abstract:

This chapter focuses primarily on four fungi, , , , and , but also considers examples from other fungal pathogens. The primary goal in this chapter is to focus on the general principles involved in the acquired immune response to fungi. Major human fungal pathogens and medical conditions predisposing to invasive disease have been discussed in the chapter. For many bacterial and viral pathogens the importance of acquired immunity is evident from the observation that recovery from symptomatic infection results in long-lasting immunity. Nevertheless, for several fungal pathogens, serological skin reactivity surveys indicate that infections are common but clinical disease is rare, consistent with the development of acquired immunity. Hence, the experience with experimental vaccines against fungi indicates that acquired immunity can be protective against fungi and that both arms of the immune system can be effective depending on the antigen used and the fungal pathogen in question. For many fungal pathogens, the effective tissue response to invasion is granulomatous inflammation. Given that an extensive body of evidence indicates an important role for acquired immunity in host defense against fungal pathogens, it is nevertheless important to consider certain caveats with regard to the studies performed in this field.

Citation: Casadevall A. 2002. Acquired Immunity against Fungi, p 223-234. In Kaufmann S, Sher A, Ahmed R (ed), Immunology of Infectious Diseases. ASM Press, Washington, DC. doi: 10.1128/9781555817978.ch16

Key Concept Ranking

Humoral Immune Response
0.4943501
T Helper Cells
0.4685425
Immune Systems
0.45790353
Tumor Necrosis Factor
0.45513797
0.4943501
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

References

/content/book/10.1128/9781555817978.chap16
1. Aguirre, K.,, E. A. Havell,, G. W. Gibson,, and L. L. Johnson. 1995. Role of tumor necrosis factor and gamma interferon in acquired resistance to Cryptococcus neoformans in the central nervous system of mice. Infect. Immun. 63: 1725 1731.
2. Aguirre, K. M.,, and L. L. Johnson. 1997. A role for B cells in resistance to Cryptococcus neoformans in mice. Infect. Immun. 65: 525 530.
3. Allen, J. E.,, and R. M. Maizels. 1997. Th1-Th2: reliable paradigm or dangerous dogma. Immunol. Today 18: 387 392.
4. Allendoerfer, R.,, G. D. Brunner,, and G. S. Deepe, Jr. 1999. Complex requirements for nascent and memory immunity in pulmonary histoplasmosis. J. Immunol. 162: 7389 7396.
5. Allendoerfer, R.,, and G. S. Deepe, Jr. 1998. Blockade of endogenous TNF-alpha exacerbates primary and secondary pulmonary histoplasmosis by differential mechanisms. J. Immunol. 160: 6072 6082.
6. Allendoerfer, R.,, D. M. Magee,, G. S. Deepe, Jr.,, and J. R. Graybill. 1993. Transfer of protective immunity in murine histoplasmosis by a CD4 + T-cell clone. Infect. Immun. 61: 714 718.
7. Ashman, R. B. 1997. Genetic determination of susceptibility and resistance in the pathogenesis of Candida albicans infection. FEMS Immunol. Med. Microbiol. 19: 183 189.
8. Ashman, R. B.,, A. Fulurija,, and J. M. Papadimitriou. 1999. Both CD4 + and CD8 + lymphocytes reduce the severity of tissue lesions in murine systemic cadidiasis, and CD4 + cells also demonstrate strain-specific immunopathological effects. Microbiology 145: 1631 1640.
9. Ashman, R. B.,, and J. M. Papadimitriou. 1995. Production and function of cytokines in natureal and acquired immunity to Candida albicans infection. Microbiol. Rev. 59: 646 672.
10. Balish, E.,, F. A. Vazquez-Torres,, J. Jones-Carson,, R. D. Wagner,, and T. Warner. 1996. Importance of β 2-microglobulin in murine resistance to mucosal and systemic candidiasis. Infect. Immun. 64: 5092 5097.
11. Balish, E.,, R. D. Wagner,, A. Vazquez-Torres,, C. Pierson,, and T. Warner. 1998. Candidiasis in interferon-gamma knockout (IFNgamma-/ -) mice. J. Infect. Dis. 178: 478 487.
12. Beaman, L.,, D. Pappagianis,, and E. Benjamini. 1977. Significance of T cells in resistance to experimental murine coccidioidomycosis. Infect. Immun. 17: 580 585.
13. Bennett, J. E. 1981. Cryptococcal skin test antigen: preparation variables and characterization. Infect. Immun. 32: 373 380.
14. Calich, V. L.,, C. A. Vaz,, and E. Burger. 1998. Immunity to Paracoccidioides brasiliensis infection. Res. Immunol. 149: 407 417.
15. Casadevall, A. 1995. Antibody immunity and invasive fungal infections. Infect. Immun. 63: 4211 4218.
16. Casadevall, A.,, A. Cassone,, F. Bistoni,, J. E. Cutler,, W. Magliani,, J. W. Murphy,, L. Polonelli,, and L. Romani. 1998. Antibody and/or cell-mediated immunity, protective mechanisms in fungal disease: an ongoing dilemma or an unnecessary dispute? Med. Mycol. 36: 95 105.
17. Casadevall, A.,, J. Mukherjee,, S. J. N. Devi,, R. Schneerson,, J. B. Robbins,, and M. D. Scharff. 1992. Antibodies elicited by a Cryptococcus neoformans glucuronoxylomannan-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection. J. Infect. Dis. 65: 1086 1093.
18. Casadevall, A.,, and J. R. Perfect. 1998. Cryptococcus neoformans. American Society for Microbiology. Washington, D.C.
19. Casadevall, A.,, and M. D. Scharff. 1991. The mouse antibody response to infection with Cryptococcus neoformans: VH and VL usage in polysaccharide binding antibodies. J. Exp. Med. 174: 151 160.
20. Cenci, E.,, A. Mencacci,, G. Del Sero,, A. Bacci,, C. Montagnoli,, C. F. d’Ostiani,, P. Mosci,, M. Bachmann,, F. Bistoni,, M. Kopf,, and L. Romani. 1999. Interleukin-4 causes susceptibility to invasive pulmonary aspergillosis through suppression of protective type I responses. J. Infect. Dis. 180: 1957 1968.
21. Chen, L.-C.,, D. L. Goldman,, T. L. Doering,, L. Pirofski,, and A. Casadevall. 1999. Antibody response to Cryptococcus neoformans proteins in rodents and humans. Infect. Immun. 67: 2218 2224.
22. Cox, R. A.,, and D. M. Magee. 1998. Protective immunity in coccidioidomycosis. Res. Immunol. 148: 417 428.
23. Currie, B. P.,, and A. Casadevall. 1994. Estimation of the prevalence of cryptococcal infection among HIV infected individuals in New York City. Clin. Infect. Dis. 19: 1029 1033.
24. De Bernardis, F.,, M. Boccanera,, D. Adriani,, E. Spreghini,, G. Santoni,, and A. Cassone. 1997. Protective role of antimannan and anti-aspartyl proteinase antibodies in an experimental model of Candida albicans vaginitis in rats. Infect. Immun. 65: 3399 3405.
25. Decken, K.,, G. Kohler,, K. Palmer-Lehmann,, A. Wunderlin,, F. Mattner,, J. Magram,, M. K. Gately,, and G. Alber. 1998. Interleukin- 12 is essential for a protective Th1 response in mice infected with Cryptococcus neoformans. Infect. Immun. 66: 4994 5000.
26. Deepe, G. S., Jr. 1994. Role of CD8 + T cells in host resistance to systemic infection with Histoplasma capsulatum in mice. J. Immunol. 152: 3491 3500.
27. Deepe, G. S., Jr. 1997. Prospects for the development of fungal vaccines. Clin. Microbiol. Rev. 10: 585 596.
28. Deepe, G. S., Jr.,, and W. E. Bullock,. 1992. Histoplasmosis. A granulomatous inflammatory response, p. 943 958. In J. I. Gallin,, I. M. Goldstein,, and R. Snyderman (ed.), Inflammation: Basic Principles and Clinical Correlates. Raven Press, New York, N.Y.
29. Deepe, G. S., Jr.,, and R. A. Seder. 1998. Molecular and cellular determinants of immunity to Histoplasma capsulatum. Res. Immunol. 149: 397 406.
30. DeShaw, M.,, and L.-A. Pirofski. 1995. Antibodies to the Cryptococcus neoformans capsular glucuronoxylomannan are ubiquitous in serum from HIV+ and HIV− individuals. Clin. Exp. Immunol. 99: 425 432.
31. Devi, S. J. N. 1996. Preclinical efficacy of a glucuronoxylomannantetanus toxoid conjugate vaccine of Cryptococcus neoformans in a murine model. Vaccine 14: 841 842.
32. Devi, S. J. N.,, R. Schneerson,, W. Egan,, T. J. Ulrich,, D. Bryla,, J. B. Robbins,, and J. E. Bennett. 1991. Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity. Infect. Immun. 59: 3700 3707.
33. Di Salvo, A. F., 2000. Blastomyces dermatitidis, p. 337 355. In L. Ajello, and R. J. Hay (ed.), Topley & Wilson’s Microbiology and Microbial Infections. Edward Arnold, London, United Kingdom.
34. Dixon, D. M.,, A. Casadevall,, B. Klein,, L. R. Travassos,, and G. Deepe. 1998. Development of vaccines and their use in the prevention of fungal infections. Med. Mycol. 36(Suppl.): 57 67.
35. Dixon, D. M.,, M. M. McNeil,, M. L. Cohen,, B. G. Gellin,, and J. R. LaMontagne. 1996. Fungal infections. A growing threat. Public Health Rep. 111: 226 235.
36. Dromer, F.,, J. Charreire,, A. Contrepois,, C. Carbon,, and P. Yeni. 1987. Protection of mice against experimental cryptococcosis by anti- Cryptococcus neoformans monoclonal antibody. Infect. Immun. 55: 749 752.
37. Feldmesser, M.,, and A. Casadevall. 1997. Effect of serum IgG1 against murine pulmonary infection with Cryptococcus neoformans. J. Immunol. 158: 790 799.
38. Fidel, P. L., Jr.,, and J. D. Sobel. 1998. Protective immunity in experimental Candida vaginitis. Res. Immunol. 149: 361 373.
39. Fidel, P. L., Jr.,, J. A. Vazquez,, and J. D. Sobel. 1999. Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin. Microbiol. Rev. 12: 80 96.
40. Fierer, J.,, L. Walls,, L. Eckmann,, T. Yamamoto,, and T. N. Kirkland. 1998. Importance of interleukin-10 in genetic susceptibility of mice to Coccidioides immitis. Infect. Immun. 66: 4397 4402.
41. Fleuridor, R.,, R. H. Lyles,, and L. Pirofski. 1999. Quantitative and qualitative differences in the serum antibody profiles of human immunodeficiency virus-infected persons with and without Cryptococcus neoformans meningitis. J. Infect. Dis. 180: 1526 1535.
42. Fresno, M.,, M. Kopf,, and L. Rivas. 1997. Cytokines and infectious diseases. Immunol. Today 18: 56 58.
43. Goldman, D.,, S. C. Lee,, and A. Casadevall. 1994. Pathogenesis of pulmonary Cryptococcus neoformans infection in the rat. Infect. Immun. 62: 4755 4761.
44. Goldman, D. L.,, S. C. Lee,, A. J. Mednic,, L. Montell,, and A. Casadevall, 2000. Persistent Cryptococcus neoformans infection in the rat is associated with intracellular parasitism, decreased inducible nitric oxide synthase expression, and altered antibody responsiveness. Infect. Immun. 68: 832 838.
45. Gomez, F. J.,, R. Allendoerfer,, and G. S. Deepe, Jr. 1995. Vaccination with recombinant heat shock protein 60 from Histoplasma capsulatum protects mice against pulmonary histoplasmosis. Infect. Immun. 63: 2587 2595.
46. Gomez, F. J.,, J. A. Cain,, R. Gibbons,, R. Allendoerfer,, and G. S. Deepe, Jr. 1998. Vbeta4 (+)Tcells promote clearance of infection in murine pulmonary histoplasmosis. J. Clin. Investig. 102: 984 995.
47. Grunig, G.,, D. B. Corry,, M. W. Leach,, B. W. Seymour,, V. P. Kurup,, and D. M. Rennick. 1997. Interleukin-10 is a natural suppressor of cytokine production and inflammation in a murine model of allergic bronchopulmonary aspergillosis. J. Exp. Med. 185: 1089 1099.
48. Han, Y.,, and J. E. Cutler. 1995. Antibody response that protects against disseminated candidiasis. Infect. Immun. 63: 2714 2719.
49. Han, Y.,, and J. E. Cutler. 1997. Assessment of a mouse model of neutropenia and the effect of an anti-candidiasis monoclonal antibody in these animals. J. Infect. Dis. 175: 1169 1175.
50. Han, Y.,, M. H. Riesselman,, and J. E. Cutler, 2000. Protection against candidiasis by an immunoglobulin G3 (IgG3) monoclonal antibody specific for the same mannotriose as an IgM protective antibody. Infect. Immun. 68: 1649 1654.
51. Han, Y.,, M. A. Ulrich,, and J. E. Cutler. 1999. Candida albicans mannan extract-protein conjugates induce a protective immune response against experimental candidiasis. J. Infect. Dis. 179: 1477 1484.
52. Hill, J. O. 1992. CD4 + T cells cause multinucleated giant cells to form around Cryptococcus neoformans and confine the yeast within the primary site of infection in the respiratory tract. J. Exp. Med. 175: 1685 1695.
53. Hoag, K. A.,, M. F. Lipscomb,, A. A. Izzo,, and N. E. Street. 1997. IL-12 and IFN-gamma are required for initiating the protective Th1 response to pulmonary cryptococcosis in resistant C.B-17 mice. Am. J. Respir. Cell Mol. Biol. 17: 733 739.
54. Hoag, K. A.,, N. E. Street,, G. B. Huffnagle,, and M. F. Lipscomb. 1995. Early cytokine production in pulmonary Cryptococcus neoformans infections distinguishes susceptible and resistant mice. Am. J. Respir. Cell Mol. Biol. 13: 487 495.
55. Hobbs, M. M.,, J. R. Perfect,, D. L. Granger,, and D. T. Durack. 1990. Opsonic activity of cerebrospinal fluid in experimental cryptococcal meningitis. Infect. Immun. 58: 2115 2119.
56. Hogan, L. H.,, S. M. Levitz,, and B. S. Klein. 1996. Virulence factors of medically important fungi. Clin. Microbiol. Rev. 9: 469 488.
57. Huffnagle, G. B. 1996. Role of cytokines in T cell immunity to a pulmonary Cryptococcus neoformans infection. Biol. Signals 5: 215 222.
58. Huffnagle, G. B.,, M. F. Lipscomb,, J. A. Lovchik,, K. A. Hoag,, and N. E. Street. 1994. The role of CD4 + and CD8 +T-cells in protective inflammatory response to a pulmonary cryptococcal infection. J. Leukoc. Biol. 55: 35 42.
59. Huffnagle, G. B.,, J. L. Yates,, and M. F. Lipscomb. 1991a. T cellmediated immunity in the lung: a Cryptococcus neoformans pulmonary infection model using SCID and athymic nude mice. Infect. Immun. 59: 1423 1433.
60. Huffnagle, G. B.,, J. L. Yates,, and M. F. Lipscomb. 1991b. Immunity to pulmonary Cryptococcus neoformans infection requires both CD4 + and CD8 + T cells. J. Exp. Med. 173: 793 800.
61. Hung, C. Y.,, N. M. Ampel,, L. Christian,, K. R. Seshan,, and G. T. Cole, 2000. A major cell surface antigen of Coccidioides immitis which elicits both humoral and cellular immune responses. Infect. Immun. 68: 584 593.
62. Jiang, C.,, D. M. Magee,, T. N. Quitugua,, and R. A. Cox. 1999. Genetic vaccination against Coccidioides immitis: comparison of vaccine efficacy of recombinant antigen 2 and antigen 2 cDNA. Infect. Immun. 67: 630 635.
63. Kawakami, K.,, Q. M. Hossain,, T. Zhang,, Y. Koguchi,, Q. Xie,, M. Kurimoto,, and A. Saito. 1999a. Interleukin-4 weakens host resistance to pulmonary and disseminated cryptococcal infection caused by combined treatment with interferon-gamma-inducing cytokines. Cell Immunol. 197: 55 61.
64. Kawakami, K.,, Y. Koguchi,, M. H. Qureshi,, Y. Kinjo,, S. Yara,, A. Miyazato,, M. Kurimoto,, K. Takeda,, S. Akira,, and A. Saito, 2000. Reduced host resistance and Th1 response to Cryptococcus neoformans in interleukin-18 deficient mice. FEMS Microbiol. Lett. 186: 121 126.
65. Kawakami, K.,, M. H. Qureshi,, T. Zhang,, Y. Koguchi,, K. Shibuya,, S. Naoe,, and A. Saito. 1999b. Interferon-gamma (IFN-gamma)- dependent protection and synthesis of chemoattractants for mononuclear leucocytes caused by IL-12 in the lungs of mice infected with Cryptococcus neoformans. Clin. Exp. Immunol. 117: 113 122.
66. Kirkland, T. N.,, F. Finley,, K. I. Orsborn,, and J. N. Galgiani. 1998a. Evaluation of the proline-rich antigen of Coccidioides immitis as a vaccine candidate in mice. Infect. Immun. 66: 3519 3522.
67. Kirkland, T. N.,, P. W. Thomas,, F. Finley,, and G. T. Cole. 1998b. Immunogenicity of a 48-kilodalton recombinant T-cell-reactive protein of Coccidioides immitis. Infect. Immun. 66: 424 431.
68. Klein, B. S.,, P. M. Sondel,, and J. M. Jones. 1992. WI-1, a novel 120-kilodalton surface protein on Blastomyces dermatitidis yeast cells, is a target antigen of cell-mediated immunity in human blastomycosis. Infect. Immun. 60: 4291 4300.
69. Kong, Y.,, and H. B. Levine. 1967. Experimentally induced immunity in the mycoses. Bacteriol. Rev. 31: 35 53.
70. Kozel, T. R.,, B. C. H. deJong,, M. M. Grinsell,, R. S. MacGill,, and K. K. Wall. 1998a. Characterization of anti-capsular monoclonal antibodies that regulate activation of the complement system by Cryptococcus neoformans. Infect. Immun. 66: 1538 1546.
71. Kozel, T. R.,, R. S. MacGill,, and K. K. Wall. 1998b. Bivalency is required for anticapsular monoclonal antibodies to optimally suppress activation of the alternative complement pathway by the Cryptococcus neoformans capsule. Infect. Immun. 66: 1547 1553.
72. Latge, J. P. 1999. Aspergillus fumigatus and aspergillosis. Clin. Microbiol. Rev. 12: 310 350.
73. Lendvai, N.,, A. Casadevall,, Z. Liang,, D. L. Goldman,, J. Mukherjee,, and L. Zuckier. 1998. Effect of immune mechanisms on the pharmacokinetics and organ distribution of cryptococcal polysaccharide. J. Infect. Dis. 177: 1647 1659.
74. Lendvai, N.,, X. Qu,, W. Hsueh,, and A. Casadevall, 2000. Mechanism for the isotype dependence of antibody-mediated toxicity in Cryptococcus neoformans infected mice. J. Immunol. 164: 4367 4374.
75. Levitz, S. M.,, H. L. Mathews,, and J. W. Murphy. 1995. Direct antimicrobial activity by T cells. Immunol. Today 16: 387 391.
76. Lim, T. S.,, and J. W. Murphy. 1980. Transfer of immunity to cryptococcosis by T-enriched splenic lymphocytes from Cryptococcus neoformans-sensitized mice. Infect. Immun. 30: 5 11.
77. Lipscomb, M. F.,, G. B. Huffnagle,, J. A. Lovchik,, C. R. Lyons,, A. M. Pollard,, and J. L. Yates. 1993. The role of T lymphocytes in pulmonary microbial defense mechanisms. Arch. Pathol. Lab. Med. 117: 1225 1232.
78. Lovchik, J. A.,, C. R. Lyons,, and M. F. Lipscomb. 1995. A role for gamma interferon-induced nitric oxide in pulmonary clearance of Cryptococcus neoformans. Am. J. Respir. Cell Mol. Biol. 13: 116 124.
79. Lovchik, J. A.,, J. A. Wilder,, G. B. Huffnagle,, R. Riblet,, C. R. Lyons,, and M. F. Lipscomb. 1999. Ig heavy chain complexlinked genes influence the immune response in a murine cryptococcal infection. J. Immunol. 163: 3907 3913.
80. Magee, D. M.,, and R. A. Cox. 1995. Roles of gamma interferon and interleukin-4 in genetically determined resistance to Coccidioides immitis. Infect. Immun. 63: 3514 3519.
81. Magee, D. M.,, and R. A. Cox. 1996. Interleukin-12 regulation of host defenses against Coccidioides immitis. Infect. Immun. 64: 3609 3613.
82. Magliani, W.,, S. Conti,, F. De Bernardis,, M. Gerloni,, D. Bertolotti,, P. Mozzoni,, A. Cassone,, and L. Polonelli. 1997. Therapeutic potential of antiidiotypic single chain antibodies with yeast killer toxin activity. Nat. Biotechnol. 15: 155 158.
83. Marino, M. W.,, A. Dunn,, D. Grail,, M. Inglese,, Y. Noguchi,, E. Richards,, A. Jungbluth,, H. Wada,, M. Moore,, B. Williamson,, S. Basu,, and L. J. Old. 1997. Characterization of tumor necrosis factor-deficient mice. Proc. Natl. Acad. Sci. USA 94: 8093 8098.
84. Matthews, R.,, and J. Burnie,. 1998. Mycoserology, p. 89 109. In L. Ajello, and R. J. Hay (ed.), Topley & Wilson’s Microbiology and Microbial Infections, vol. 4. Edward Arnold, London, United Kingdom.
85. Matthews, R. C.,, and J. P. Burnie. 1996. Antibodies and Candida: potential therapeutics. Trends Microbiol. 4: 354 358.
86. Matthews, R. C.,, J. P. Burnie,, D. Howat,, T. Rowland,, and F. Walton. 1991. Autoantibody to heat shock protein 90 can mediate protection against systemic candidosis. Immunology 74: 20 24.
87. Monari, C.,, A. Casadevall,, C. Retini,, F. Baldelli,, F. Bistoni,, and A. Vecchiarelli. 1999. Antibody to capsular polysaccharide enhances the function of neutrophils from patients with AIDS against Cryptococcus neoformans. AIDS 13: 653 660.
88. Monga, D. P.,, R. Kumar,, L. N. Mahapatra,, and A. N. Malaviya. 1979. Experimental cryptococcosis in normal and B-cell deficient mice. Infect. Immun. 26: 1 3.
89. Mukherjee, J.,, G. Nussbaum,, M. D. Scharff,, and A. Casadevall. 1995a. Protective and non-protective monoclonal antibodies to Cryptococcus neoformans originating from one B-cell. J. Exp. Med. 181: 405 409.
90. Mukherjee, J.,, L. Pirofski,, M. D. Scharff,, and A. Casadevall. 1993. Antibody mediated protection in mice with lethal intracerebral Cryptococcus neoformans infection. Proc. Natl. Acad. Sci. USA 90: 3636 3640.
91. Mukherjee, J.,, M. D. Scharff,, and A. Casadevall. 1992. Protective murine monoclonal antibodies to Cryptococcus neoformans. Infect. Immun. 60: 4534 4541.
92. Mukherjee, S.,, M. Feldmesser,, and A. Casadevall. 1996. J774 murine macrophage-like cell interactions with Cryptococcus neoformans in the presence and absence of opsonins. J. Infect. Dis. 173: 1222 1231.
93. Mukherjee, S.,, S. C. Lee,, and A. Casadevall. 1995b. Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages. Infect. Immun. 63: 573 579.
94. Murphy, J. W. 1991. Mechanisms of natural resistance to human pathogenic fungi. Annu. Rev. Microbiol. 45: 509 538.
95. Murphy, J. W. 1998. Protective cell-mediated immunity against Cryptococcus neoformans. Res. Immunol. 149: 373 386.
96. Nagai, H.,, J. Guo,, H. Choi,, and V. Kurup. 1995. Interferongamma and tumor necrosis factor-alpha protect mice from invasive aspergillosis. J. Infect. Dis. 172: 1554 1560.
97. Pietrella, D.,, C. Monari,, C. Retini,, B. Palazzetti,, T. R. Kozel,, and A. Vecchiarelli. 1998. Cryptococcus neoformans and Candida albicans regulate CD4 expression on human monocytes. J. Infect. Dis. 178: 1464 1471.
98. Pirofski, L.,, and A. Casadevall. 1996. Antibody immunity to Cryptococcus neoformans: paradigm for antibody immunity to the fungi? Zentbl. Bakteriol. 284: 475 495.
99. Polonelli, L.,, F. De Bernardis,, M. Boccanera,, M. Gerloni,, G. Morace,, W. Magliani,, C. Chezzi,, and A. Cassone. 1994. Idiotypic intravaginal vaccination to protect against candidal vaginitis by secretory, yeast killer toxin-like anti-idiotypic antibodies. J. Immunol. 152: 3175 3181.
100. Qian, Q.,, and J. E. Cutler. 1997. Gamma interferon is not essential in host defense against disseminated candidiasis in mice. Infect. Immun. 65: 1748 1753.
101. Romagnani, S. 1996. Understanding the role of the Th1/Th2 cells in infection. Trends Microbiol. 4: 470 473.
102. Romani, L.,, E. Cenci,, A. Mencacci,, R. Spaccapelo,, U. Grohmann,, P. Puccetti,, and F. Bistoni. 1992a. Gamma interferon modifies CD4 + subset expression in murine candidiasis. Infect. Immun. 60: 4950 4952.
103. Romani, L.,, and D. H. Howard. 1995. Mechanisms of resistance to fungal infections. Curr. Opin. Immunol. 7: 517 523.
104. Romani, L.,, A. Mencacci,, U. Grohmann,, S. Mocci,, P. Mosci,, P. Puccetti,, and F. Bistoni. 1992b. Neutralizing antibody to interleukin 4 induces systemic protection and T helper type 1- associated immunity in murine candidiasis. J. Exp. Med. 176: 19 25.
105. Salvin, S. B. 1959. Current concepts of diagnostic serology and skin hypersensitivity in the mycoses. Am. J. Med. 27: 97 114.
106. Sanford, J. E.,, D. M. Lupan,, A. M. Schlagetter,, and T. R. Kozel. 1990. Passive immunization against Cryptococcus neoformans with an isotype-switch family of monoclonal antibodies reactive with cryptococcal polysaccharide. Infect. Immun. 58: 1919 1923.
107. Segal, E. 1987. Vaccines against fungal infections. Crit. Rev. Microbiol. 14: 229 273.
108. Tewari, R.,, L. J. Wheat,, and L. Ajello,. 1998. Agents of histoplasmosis, p. 373 393. In L. Ajello, and R. J. Hay (ed.), Topley & Wilson’s Microbiology and Microbial Infections, vol. 4. Edward Arnold, London, United Kingdom.
109. Tripp, C. S.,, K. P. Beckerman,, and E. R. Unanue. 1995. Immune complexes inhibit antimicrobial responses through interleukin- 10 production. J. Clin. Investig. 95: 1628 1694.
110. van Enckevort, F. H.,, M. G. Netea,, A. R. Hermus,, C. G. Sweep,, J. F. Meis,, J. W. Van der Meer,, and B. J. Kullberg. 1999. In creased susceptibility to systemic candidiasis in interleukin-6 deficient mice. Med. Mycol. 37: 419 426.
111. Vazquez-Torres, A.,, and E. Balish. 1997. Macrophages in resistance to candidiasis. Microbiol. Mol. Biol. Rev. 61: 170 192.
112. Vazquez-Torres, A.,, J. Jones-Carson,, R. D. Wagner,, T. Warner,, and E. Balish. 1999. Early resistance of interleukin-10 knockout mice to acute systemic candidiasis. Infect. Immun. 67: 670 674.
113. Vecchiarelli, A.,, and A. Casadevall. 1998. Antibody-mediated effects against Cryptococcus neoformans: evidence for interdependency and collaboration between humoral and cellular immunity. Res. Immunol. 149: 321 333.
114. Vecchiarelli, A.,, C. Monari,, C. Retini,, D. Pietrella,, B. Palazzetti,, L. Pitzurra,, and A. Casadevall. 1998a. Cryptococcus neoformans differently regulates B7-1 (CD80) and B7-2 (CD86) expression on human monocytes. Eur. J. Immunol. 28: 114 121.
115. Vecchiarelli, A.,, C. Retini,, A. Casadevall,, C. Monari,, D. Pietrella,, and T. R. Kozel. 1998b. Involvement of C3a and C5a in Interleukin- 8 secretion by human polymorphonuclear cells in response to capsular polysaccharide material of Cryptococcus neoformans. Infect. Immun. 66: 4324 4330.
116. Vecchiarelli, A.,, C. Retini,, C. Monari,, and A. Casadevall. 1998c. Specific antibody to Cryptococcus neoformans alters human leukocyte cytokine synthesis and promotes T cell proliferation. Infect. Immun. 66: 1244 1247.
117. Wagner, R. D.,, A. Vazquez-Torres,, J. Jones-Carson,, T. Warner,, and E. Balish. 1996. B cell knockout mice are resistant to mucosal and systemic candidiasis of endogenous origin but susceptible to experimental systemic candidiasis. J. Infect. Dis. 174: 589 597.
118. Wheat, J. 1995. Endemic mycoses in AIDS: a clinical review. Clin. Microbiol. Rev. 8: 146 159.
119. Wuthrich, M.,, W. L. Chang,, and B. S. Klein. 1998. Immunogenicity and protective efficacy of the WI-1 adhesin of Blastomyces dermatitidis. Infect. Immun. 66: 5443 5449.
120. Yang, M. C.,, D. M. Magee,, and R. A. Cox. 1997. Mapping of a Coccidioides immitis-specific epitope that reacts with complement- fixing antibody. Infect. Immun. 65: 4068 4074.
121. Yuan, R.,, A. Casadevall,, J. Oh,, and M. D. Scharff. 1997. T cells cooperate with passive antibody to modify Cryptococcus neoformans infection in mice. Proc. Natl. Acad. Sci. USA 94: 2483 2488.
122. Yuan, R.,, A. Casadevall,, G. Spira,, and M. D. Scharff. 1995. Isotype switching from IgG3 to IgG1 converts a non-protective murine antibody to C. neoformans into a protective antibody. J. Immunol. 154: 1810 1816.
123. Yuan, R.,, G. Spira,, J. Oh,, M. Paizi,, A. Casadevall,, and M. D. Scharff. 1998. Isotype switching increases antibody protective efficacy to Cryptococcus neoformans infection in mice. Infect. Immun. 66: 1057 1062.
124. Zhou, P.,, and R. A. Seder. 1998. CD40 ligand is not essential for induction of type 1 cytokine responses or protective immunity after primary or secondary infection with histoplasma capsulatum. J. Exp. Med. 187: 1315 1324.
125. Zhou, P.,, M. C. Sieve,, J. Bennett,, K. J. Kwon-Chung,, R. P. Tewari,, R. T. Gazzinelli,, A. Sher,, and R. A. Seder. 1995. IL-12 prevents mortality in mice infected with Histoplasma capsulatum through induction of IFN-gamma. J. Immunol. 155: 785 795.
126. Zhu, Y.,, V. Tryon,, D. M. Magee,, and R. A. Cox. 1997. Identification of a Coccidioides immitis antigen 2 domain that expresses B-cell-reactive epitopes. Infect. Immun. 65: 3376 3380.

Tables

Generic image for table
Table 1

Major human fungal pathogens and medical conditions predisposing to invasive disease

Citation: Casadevall A. 2002. Acquired Immunity against Fungi, p 223-234. In Kaufmann S, Sher A, Ahmed R (ed), Immunology of Infectious Diseases. ASM Press, Washington, DC. doi: 10.1128/9781555817978.ch16
Generic image for table
Table 2

Examples of mouse experiments that indicate the importance of the acquired immune system

Citation: Casadevall A. 2002. Acquired Immunity against Fungi, p 223-234. In Kaufmann S, Sher A, Ahmed R (ed), Immunology of Infectious Diseases. ASM Press, Washington, DC. doi: 10.1128/9781555817978.ch16

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error